A nano fluorescent probe for specific gallbladder delivery, preparation method and application thereof
By designing nanofluorescent probes delivered specifically for gallbladder, using amphiphilic brush-like polymer structures and metal chelates, the problems of low penetration depth and poor specificity of fluorescent surgical navigation in gallbladder disease surgery are solved, achieving high efficiency , low-dose gallbladder imaging, with wide applicability and low toxicity, suitable for clinical applications.
Patent Information
- Application Number
- CN202211473802.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-11-22
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2042-11-22
AI Technical Summary
The existing fluorescent surgical navigation technology has low penetration depth, poor specificity, large doses, and discomfortable to the state of the gallbladder in gallbladder surgery, making it difficult to achieve high-precision gallbladder imaging.
A nanofluorescent probe for specific gallbladder delivery was developed using an amphiphilic brush-like polymer structure, including brush-like hydrophilic segments, hydrophobic segments and fluorescent groups, which quickly enter the gallbladder after intravenous injection. , metal chelates are used to enhance fluorescence efficiency and emission wavelength to achieve efficient gallbladder imaging.
It realizes efficient gallbladder imaging, has good specificity and biocompatibility, avoids retention of fluorescent probes in the liver, has a wide range of application and low cost, is suitable for mass production and has clinical application potential.
Smart Images

Figure CN115887702B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of nano-biomaterials, and in particular to a nano-fluorescent probe for specific gallbladder delivery, a preparation method and application thereof. Background Art
[0002] The incidence of gallbladder system diseases has been on the rise in recent years, which has seriously threatened the life and health of patients. Currently, the imaging methods for gallbladder include MRI, CT and ultrasound. These imaging analyses can be used to diagnose gallbladder diseases such as gallbladder cancer, gallstones, cholecystitis, etc., but these technologies cannot achieve intraoperative surgical guidance. Since some gallbladder diseases require surgical treatment, laparoscopic surgical guidance is particularly important for gallbladder surgical guidance. Since the lesions of some gallbladder diseases are small, micro-biliary fistulas may occur during surgery, and it is difficult to fully observe the location of bile fistulas or extremely small lesions through laparoscopy. Therefore, fluorescent surgical navigation is particularly important in hepatobiliary surgery. At present, ICG (indocyanine green) has been used clinically as a fluorescent agent for fluorescent surgical navigation in hepatobiliary surgery. As an organic dye, ICG is enriched in the liver after intravenous injection, but it is difficult to enrich in the gallbladder when metabolized by the liver. Therefore, ICG can hardly be used for imaging of the gallbladder system after intravenous injection. At present, the most effective method of using ICG for gallbladder and bile duct imaging is direct injection through the gallbladder, but this method has certain limitations. For example, if the patient's gallbladder is in poor condition (gallbladder atrophy, gangrene, etc.), it will cause leakage at the puncture point, resulting in ICG contamination of the intraoperative field of view, or if the patient's gallbladder wall is thick, ICG injection into the gallbladder seromuscular layer will also cause bile to be non-fluorescent. In addition, the emission wavelength of ICG is around 800nm, and the penetration depth of tissue is about 1-3.5mm, which is insufficient to meet the needs of high-precision imaging in response to complex pathophysiological conditions. Therefore, it is particularly important to develop fluorescent agents with higher emission wavelengths for specific gallbladder delivery, and it has great prospects for clinical application.
[0003] The molecular design of most organic fluorophores is relatively complex, so the cost is relatively high. Since the main structure has a large number of conjugated groups, the water solubility is generally poor. Generally speaking, the water solubility is increased by modifying the sulfonate group on the organic fluorophore, or the hydrophilicity is increased by self-assembly of amphiphilic macromolecules such as liposomes. Both of these methods of increasing the water solubility of organic fluorophores will cause the fluorescent probe to remain in the liver for a long time, and cannot be effectively retained in the gallbladder to achieve the effect of fluorescence imaging.
[0004] In view of the above-mentioned defects, the inventors of the present invention finally obtained the present invention after a long period of research and practice. Summary of the invention
[0005] The purpose of the present invention is to solve the problems of low penetration depth, poor specificity, invasive damage and large ICG dosage in the current clinical gallbladder fluorescence surgical navigation, and provide a nano fluorescent probe for specific gallbladder delivery, a preparation method and an application thereof according to the metabolic characteristics of the hepatobiliary system.
[0006] In order to achieve the above object, the present invention discloses a nano fluorescent probe for specific gallbladder delivery, wherein the nano fluorescent probe is an amphiphilic brush polymer, including a brush-like hydrophilic segment, a hydrophobic segment and a fluorescent group, and the structural formula of the nano fluorescent probe is as follows:
[0007]
[0008] Wherein, R1 is H or CH3, R2 is a functional group, R3 is CH3, C2H5 or C4H9, R4 is ICG, IR-783, IR-808, IR-820, IR-1061 or Cy5.5 and its derivatives, x is 10 to 200, y is 1 to 20, z is 10 to 300, m is 0.01 to 1, and n is 3 to 100.
[0009] The R2 is a chelate of DO3A, DOTA, NOTA, DTPA and their derivatives with metals.
[0010] The metal is a lanthanide element.
[0011] The hydrated particle size of the nano fluorescent probe is 15 to 500 nm.
[0012] The hydrated particle size of the nano fluorescent probe is 40 to 200 nm.
[0013] The emission wavelength of the fluorescent probe is 500nm to 1700nm, and preferably the excitation wavelength is 700nm to 1100nm.
[0014] The emission wavelength of the fluorescent probe is 1000nm-1500nm, and preferably the excitation wavelength is 780nm, 808nm, 980nm or 1060nm.
[0015] The present invention also discloses a method for preparing the above-mentioned nano fluorescent probe for specific gallbladder delivery, comprising the following steps:
[0016] S1, preparing a dye monomer: introducing a (meth)acrylate bond or a (meth)acrylamide bond into an organic dye through a substitution reaction to obtain a dye monomer;
[0017] S2, preparing an amphiphilic brush polymer containing a fluorophore: block copolymerizing (meth) acrylate polyethylene glycol with a functional monomer, a (meth) acrylate monomer and a dye monomer by controlled free radical polymerization to obtain an amphiphilic brush polymer;
[0018] S3, preparing a nano fluorescent probe: dissolving the amphiphilic brush polymer obtained in step S2 in an aqueous phase to obtain a nano fluorescent probe.
[0019] The aqueous phase in step S3 is any one or two of PBS, physiological saline or medical glucose injection.
[0020] The nano fluorescent probe for specific gallbladder delivery prepared by the present invention can effectively avoid the concentration quenching effect and improve the fluorescence efficiency because the fluorescent dye is in the hydrophobic segment and the amount added is small. In addition, due to the amphiphilic structure of the polymer, after the fluorescent dye is excited in the hydrophobic segment, a torsional intramolecular charge transfer will occur, and the emission wavelength will be red-shifted. The metal chelate on the brush polymer will increase the tail peak emission intensity of the fluorescent dye through the heavy atom effect and photoelectron transfer, thereby increasing the detection wavelength range of the nano fluorescent probe, including the emission in the near-infrared region II.
[0021] The present invention also discloses the application of the above-mentioned specific gallbladder-delivered nanofluorescent probe. After intravenous injection, the nanofluorescent probe enters the liver sinusoids through the blood circulation, enters the bile ductules through the rapid action of liver cells, and then is enriched and retained in the gallbladder.
[0022] The fluorescent probe enters the gallbladder 1 to 15 minutes after intravenous injection, is metabolized by the liver by more than 90% within 30 to 120 minutes, and stays in the gallbladder for 1 to 48 hours.
[0023] The application scenarios of the nanoprobe are fluorescence imaging of the hepatobiliary system and fluorescence surgical navigation of hepatobiliary diseases.
[0024] Compared with the prior art, the beneficial effects of the present invention are:
[0025] 1. The present invention creatively utilizes the anti-protein adsorption ability of PEG to construct the amphiphilic polymer of PEG brush, and uses the bonding method to load the fluorescent dye, which is metabolized by the liver at a very fast speed. The bonding method can effectively prevent the nano fluorescent probe from being phagocytosed and retained for a long time by Kupffer cells, liver sinusoidal endothelial cells and hepatocytes, allowing the fluorescent probe to enter the gallbladder intact, thereby achieving an efficient gallbladder delivery effect;
[0026] 2. The nano fluorescent probe of the present invention has excellent gallbladder specificity. After intravenous injection, almost no signal appears in other tissues and organs, and the metabolism rate is fast. There is almost no signal in the liver 1-2 hours after injection;
[0027] 3. The nano fluorescent probe of the present invention has a simple preparation method, low cost, can be mass-produced, and has a wide range of size applications and strong controllability;
[0028] 4. The nano fluorescent probe of the present invention has good biocompatibility, low toxicity and great potential for clinical application. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 DLS graphs of nano fluorescent probes of different sizes for specific gallbladder delivery prepared in Examples 1-3 of the present invention;
[0030] Figure 2 TEM images of the nano fluorescent probe P30 for specific gallbladder delivery prepared in Examples 1 and 3 of the present invention;
[0031] Figure 3 Comparison chart of blood biochemical indexes of BALB / c mice injected with the nano fluorescent probe P30 for specific gallbladder delivery prepared in Example 1 and Example 3 of the present invention through tail vein and compared with the blank control group;
[0032] Figure 4 The H&E staining comparison chart of the main organs of BALB / c mice injected with the nano fluorescent probe P30 for specific gallbladder delivery prepared in Example 1 and Example 3 of the present invention through the tail vein compared with the blank control group;
[0033] Figure 5 The nano fluorescent probe P30 for specific gallbladder delivery prepared in Example 1 and Example 4 of the present invention was injected into BALB / c mice via the tail vein, and the fluorescence imaging effect diagram at various time points within 1 hour was observed under a near-infrared zone II fluorescence imager;
[0034] Figure 6 The nano fluorescent probes P20 and P60 prepared in Example 2 and Example 4 of the present invention for specific gallbladder delivery were injected into BALB / c mice via the tail vein, and the fluorescence imaging effect diagram at 1 hour was observed under a near-infrared zone II fluorescence imager;
[0035] Figure 7 The nano fluorescent probe P40 for specific gallbladder delivery prepared in Example 2 and Example 5 of the present invention was injected into New Zealand rabbits via the auricular vein. The liver was dissected 1 hour later, and the fluorescence imaging effect diagram was observed under a near-infrared zone II fluorescence imager. DETAILED DESCRIPTION
[0036] The above and other technical features and advantages of the present invention are described in more detail below in conjunction with the accompanying drawings.
[0037] Example 1
[0038] S1: Preparation of dye monomers:
[0039] (1) Synthesis of IR-808: 750 mg IR-783 (CAS: 115970-66-6) and 200 mg p-mercaptobenzoic acid were dissolved in 10 mL DMF and stirred at room temperature for 24 h. After the reaction was completed, the mixture was precipitated in ether to obtain 890 mg IR-808.
[0040] (2) Synthesis of MA-IR-808: The IR-808 obtained in the previous step was dissolved in anhydrous DMF with 300 mg DCC and 200 mg N-hydroxysuccinimide and stirred in an ice bath for 30 min. Then 300 mg 2-aminoethyl methacrylate was added and reacted at 40°C for 24 h. After the reaction was completed, the insoluble matter was filtered out and then precipitated in diethyl ether to obtain 913 mg MA-IR-808.
[0041] S2: Preparation of amphiphilic brush polymers containing fluorophores:
[0042] (1) Preparation of hydrophilic segments: 1.5 g of oligomeric polyethylene glycol methacrylate monomethyl ether (Mw 300), 28 mg of 4-cyano-4-(thiobenzoyl)pentanoic acid and 0.3 g of MA-DO3A-tBu were dissolved in 10 mL of 1,4-dioxane, and then 4 mg of AIBN was added. The mixed solution was deoxygenated and polymerized at 70°C for 18 h. After the polymerization was completed, the mixture was precipitated in n-hexane to obtain 1.6 g of P-(OEGMA-co-DO3A) hydrophilic segments.
[0043] (2) Preparation of amphiphilic polymer: The above hydrophilic segment P-(OEGMA-co-DO3A) was used as a macromolecular chain transfer agent and dissolved in 10 mL DMF with 426 mg butyl methacrylate and 10 mg MA-IR-808, followed by the addition of 6 mg AIBN. The mixed solution was deoxygenated and polymerized at 70°C for 18 h. After the polymerization, the mixture was precipitated in n-hexane to obtain 1.92 g of an amphiphilic polymer P-(OEGMA-co-DO3A)-b-(nBMA-co-IR-808).
[0044] (3) Chelation of Nd element: P-(OEGMA-co-DO3A)-b-(nBMA-co-IR-808) obtained in the previous step was dissolved in 10 mL of DCM, and 10 mL of trifluoroacetic acid was added. The mixture was stirred at room temperature for 4 h, and then all the solvent was dried by vortexing. The remaining solid was dissolved in deionized water, and 300 mg of NdCl3·6H2O was added. The pH was adjusted to 7-8 with ammonium acetate, and the reaction was carried out at 60°C overnight to obtain an amphiphilic polymer containing a fluorophore.
[0045] S3: Preparation of nanofluorescent probes: The amphiphilic polymer containing fluorophores obtained in S2 was dissolved in PBS, and the concentration was determined to be 0.5 mg / mL (MA-IR-808 equivalent) by UV-visible absorption spectrometer, recorded as P30.
[0046] Example 2
[0047] S1: Preparation of amphiphilic brush polymers containing fluorophores:
[0048] (1) Preparation of hydrophilic segments: 6 g of oligomeric polyethylene glycol methacrylate monomethyl ether (Mw 300), 112 mg of 4-cyano-4-(thiobenzoyl)pentanoic acid and 1.2 g of MA-DO3A-tBu were dissolved in 10 mL of 1,4-dioxane, and then 4 mg of AIBN was added. The mixed solution was deoxygenated and polymerized at 70°C for 18 h. After the polymerization was completed, the mixture was precipitated in n-hexane to obtain 6.8 g of P-(OEGMA-co-DO3A) hydrophilic segments.
[0049] (2) Preparation of amphiphilic polymers: The above hydrophilic segment P-(OEGMA-co-DO3A) was used as a macromolecular chain transfer agent and divided into four equal parts. 284 mg, 568 mg, 710 mg and 852 mg of butyl methacrylate and 10 mg of MA-IR-808 prepared in Example 1 were dissolved in 10 mL of DMF, and then 6 mg of AIBN was added. The mixed solution was deoxygenated and polymerized at 70°C for 18 h. After the polymerization was completed, the mixture was precipitated in n-hexane to obtain four amphiphilic polymers P-(OEGMA-co-DO3A)-b-(nBMA-co-IR-808) with different molecular weights.
[0050] (3) Chelation of Nd element: The four different molecular weights of P-(OEGMA-co-DO3A)-b-(nBMA-co-IR-808) obtained in the previous step were dissolved in 10 mL of DCM, and 10 mL of trifluoroacetic acid was added. The mixture was stirred at room temperature for 4 h, and then all the solvent was dried by vortexing. The remaining solid was dissolved in deionized water, and 600 mg of NdCl3·6H2O was added. The pH was adjusted to 7-8 with ammonium acetate, and the reaction was carried out at 60°C overnight to obtain an amphiphilic polymer containing a fluorophore.
[0051] S2: Preparation of nano fluorescent probes: Dissolve the 4 different molecular weights of amphiphilic polymers containing fluorophores obtained in S1 in PBS and record them as P20, P40, P50, and P60.
[0052] Example 3
[0053] P20, P30, P40, P50, and P60 prepared in Example 1 and Example 2 were diluted 5 times, and the hydrated particle size was tested by dynamic light scattering. Figure 1As shown in the figure, the hydrated particle sizes of P20, P30, P40, P50, and P60 are 37.2±0.9nm; 50.7±0.4nm; 75.2±0.8nm; 112.0±2.5nm; and 133.4±0.2nm, respectively. 0.1mL of P30 was taken and stained with phosphotungstic acid negative staining solution, and then observed under a transmission electron microscope. Figure 2 As shown, P30 was spherical in shape with a size of 49.6 ± 3.4 nm.
[0054] P30 was then injected into healthy BALB / c mice (n=5) via the tail vein. Blood and major organs (heart, liver, spleen, lung, and kidney) were collected 14 days later. The mice injected with PBS served as a blank control group. Blood biochemical indices were tested, and organ integrity was observed by H&E staining. Figure 3 As shown in the figure, blood biochemical indicators showed no significant difference between the P30 group and the blank control group. Figure 4 As shown, the main organs showed no obvious damage. This result proves that the nano fluorescent probe for specific gallbladder delivery prepared by the present invention has good biocompatibility.
[0055] Example 4
[0056] The P20, P30, and P60 prepared in Example 1 and Example 2 were respectively injected into mice through the tail vein and observed under a near-infrared zone II in vivo fluorescence imager, where the excitation light was 808 nm and the laser power density was 45 mW / cm 2 , using a 1250nm long-pass filter and a camera exposure time of 100ms.
[0057] Figure 5 This is the fluorescence imaging image within 1 hour after P30 was injected into the mouse through the tail vein. The fluorescence signal can be observed in the gallbladder 5 minutes after injection, and the liver signal weakened 15 minutes later. The fluorescence signal is mainly in the gallbladder and duodenum. After 1 hour, the abdominal cavity is opened and the gallbladder signal can be clearly observed. Figure 6 These are the fluorescence images of P20 and P60 1 hour after they were injected into mice through the tail vein. The gallbladder signal is still obvious.
[0058] The results show that the fluorescent nanoprobes of different sizes prepared by the present invention all have the characteristics of specific gallbladder delivery, and can achieve gallbladder enrichment within a large size range. Therefore, the nano fluorescent probes for specific gallbladder delivery prepared by the present invention have a wide size application range, and the small deviations produced in actual production have almost no effect on the use effect of the nano fluorescent probes.
[0059] Example 5
[0060] The P40 prepared in Example 2 was injected into New Zealand rabbits via the ear vein. One hour after the injection, the common bile duct, portal vein, hepatic artery, and hepatic vein were ligated. The rabbit liver was then removed and observed under a near-infrared zone II in vivo fluorescence imager, where the excitation light was 808 nm and the laser power density was 80 mW / cm 2 , 1200nm long pass filter, camera exposure time is 150ms. Figure 7 As shown, the rabbit gallbladder signal is obvious and the bile duct structure can be clearly observed. This result shows that the nano fluorescent probe for specific gallbladder delivery prepared by the present invention still has good gallbladder specificity in large animals and has great clinical transformation potential.
[0061] The above description is only a preferred embodiment of the present invention, which is only illustrative and not restrictive of the present invention. Those skilled in the art understand that many changes, modifications, and even equivalences may be made to the present invention within the spirit and scope defined by the claims of the present invention, but all of them will fall within the scope of protection of the present invention.
Claims
1. A nano fluorescent probe for specific gallbladder delivery, characterized in that: The preparation method of the nano fluorescent probe comprises the following steps: S1: Preparation of dye monomers: (1) Synthesis of IR-808: 750 mg of IR-783 and 200 mg of p-mercaptobenzoic acid were dissolved in 10 mL of DMF and stirred at room temperature for 24 h. After the reaction, the mixture was precipitated in ether to obtain 890 mg of IR-808. (2) Synthesis of MA-IR-808: The IR-808 obtained in the previous step was dissolved in anhydrous DMF with 300 mg DCC and 200 mg N-hydroxysuccinimide, and stirred in an ice bath for 30 min. Then, 300 mg 2-aminoethyl methacrylate was added and reacted at 40 °C for 24 h. After the reaction was completed, the insoluble matter was filtered out and then precipitated in ether to obtain 913 mg MA-IR-808. S2: Preparation of amphiphilic brush polymers containing fluorophores: (1) Preparation of hydrophilic segments: 1.5 g of oligomeric methacrylate polyethylene glycol monomethyl ether (Mw = 300) was dissolved in 10 mL of 1,4-dioxane with 28 mg of 4-cyano-4-(thiobenzoyl)pentanoic acid and 0.3 g of MA-DO3A-tBu. 4 mg of AIBN was then added. The mixed solution was deoxygenated and polymerized at 70 °C for 18 h. After the polymerization was completed, the solution was precipitated in n-hexane to obtain 1.6 g of P-(OEGMA-co-DO3A) hydrophilic segments. (2) Preparation of amphiphilic polymer: The above hydrophilic segment P-(OEGMA-co-DO3A) was used as a macromolecular chain transfer agent and dissolved in 10 mL DMF with 426 mg butyl methacrylate and 10 mg MA-IR-808. Then 6 mg AIBN was added. The mixed solution was deoxygenated and polymerized at 70 °C for 18 h. After the polymerization, it was precipitated in n-hexane to obtain 1.92 g of amphiphilic polymer P-(OEGMA-co-DO3A)-b-(nBMA-co-IR-808). (3) Chelation of Nd element: P-(OEGMA-co-DO3A)-b-(nBMA-co-IR-808) obtained in the previous step was dissolved in 10 mL of DCM, and 10 mL of trifluoroacetic acid was added. The mixture was stirred at room temperature for 4 h, and then all the solvent was dried by vortexing. The remaining solid was dissolved in deionized water, and 300 mg of NdCl3·6H2O was added. The pH was adjusted to 7-8 with ammonium acetate, and the reaction was carried out at 60°C overnight to obtain an amphiphilic polymer containing a fluorophore. S3: Preparation of nanofluorescent probes: The amphiphilic polymer containing fluorophores obtained in S2 was dissolved in PBS and the concentration was determined to be 0.5 mg / mL using a UV-visible absorption spectrometer.
2. Use of the gallbladder-specifically delivered nanofluorescent probe as claimed in claim 1 in the preparation of gallbladder imaging drugs.
